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This study is based on an a priori hypothesis for a particular SNP in the SIRT5 gene (rs9382222; 
C→T) for which we have evidence that the common C-allele is associated with an older 
biological age of the brain. Digit Symbol Substitution Test (DSST), 20 meters timed-walk (Gait 
Test) and Epidemiological Studies Depression Scale (CES-D) are functional markers of brain 
health and applicable tests to measure cognitive function, motor function and depressed mood. 
HYPOTHESIS: At baseline, subjects carrying the common C/C risk genotype at the SIRT5 SNP 
will display poorer function on cognitive function tests (lower DSST score) and motor function 
tests (longer time to walk 20 meters), and have increased self-reported symptoms of a depressed 
mood (higher CES-D score), as compared to all other subjects. METHODS: The linear model 
type, one-way analysis of covariance (ANCOVA), was fitted using SAS GLM procedure to test 
for between-group differences in functional outcomes. Concordance in SNP effects were 
investigated for the three interrelated functional markers in subjects carrying the specific 
genotype (C/C, C/T, T/T). RESULTS: We detected a borderline significant association between 
DSST and SNP in the black population (p=0.051, mean diff.=-0.05, SD=0.95) with C/C subjects 
displaying lower DSST scores vs. C/T (almost 2 units lower than heterozygotes). There is a trend 
for an association between CES-D and SNP in the white population (p=0.08, mean diff.=-1.85, 
SD=0.03) with the C/C risk group reporting higher depression-like symptoms vs. C/T. Gait Test 
were no statistical significant associated to the SNP. CONCLUSIONS: The C/C previously 
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linked with older biological brain age was associated with (1) lower DSST scores in the black 
population and (2) displayed trend-level higher CES-D depressive-like scores in the white 
population, hence suggesting the SIRT5 C/C genotype as a probable risk factor for both 
biological brain age and related functional outcomes. PUBLIC HEALTH SIGNIFICANCE: 
Emotional and cognitive fitness is rapidly becoming a major determinant to the quality of life 
during old age. Study the genetic component of the brain aging as this SNP would help  to 1) 
identify people at risk, and 2) address public health programs to achieve a successful aging. 
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1.0  INTRODUCTION 
Worldwide, the proportion of people over 60 years age is significantly increasing compared to 
other age groups [1]. Since 2002 it has been calculated that the number of old people has tripled 
over the last half century; it has been estimated it will more than triple in the next half century 
[2]. Pooled factors such as drop in fertility and increase in average life span have made this 
epidemiologic transition possible [3]. This global phenomenon is occurring at different rates 
among countries [4]. 
According to the U.S. Bureau of the Census, the World Health Organization, and the 
United Nations on U.S. and global trends in aging, the worldwide population of persons aged 
>65 years was projected to 420 million in the year 2000, increasing 9.5 million just in the year 
1999 [5]. It is estimated that from 2000 to 2030, the worldwide population aged >65 years will 
augment by approximately 550 million to 973 million [6]. Proportionally it will grow from 6.9% 
to 12.0% worldwide (15.5% to 24.3% in Europe, from 12.6% to 20.3% in North America, from 
6.0% to 12.0% in Asia, from 5.5% to 11.6% in Latin America and the Caribbean [5], and from 
2.9% in to 3.7% in Sub-Saharan Africa) with a remarkable increase in developing countries 
where it is estimated to increase almost three-fold (249 million in 2000 to an estimated 690 
million in 2030) [5]. In the developing countries the world's population aged >65 years is 
estimated to increase from 59% to 71%. The increase of persons aged >65 worldwide is already 
challenging the public health system. Medical attention and social services are the principal 
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demands by this population; they are the most likely to develop chronic illnesses which produce 
disability, decrease the quality of life, and increase medical care costs and attention. 
In the US, people over 65 years old are expected to grow from 12.4% in 2000 to 19.6% in 2030 
[6]. It means in 2030 there will be 71 million people in this age group[6]. Although Florida has 
the largest population in people over 65 years old, according to the U.S. Bureau of Census, 
Pennsylvania was one of the nine states in the country that had more than one million persons 
over 65 years old fifteen years ago [7] and it is expected to grow more than 15% by 2025 [8]. 
The expected increase of older adults is already challenging public health system. 
Chronic diseases which decrease the quality of life and increase the medical care cost have 
already required special public health interventions; however, there is a growing concern about 
the future [3]. 
Because of this epidemiology transition, quality of life has become an important issue in 
older people. It is well know that improvements in health services and living conditions have 
considerably contributed to the increased average human lifespan over the last century. As a 
result, emotional and cognitive fitness is rapidly becoming a major determinant and unmet 
challenge to the quality of life during old age. Specifically, while successful aging is achievable, 
for numerous individuals, low mood is too often an early symptom and significant contributor to 
the downward spiral of aging, which includes further cognitive and motor decline. 
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1.1 HAP-MAP PROJECT 
This project is a partnership of scientists and funding agencies from Canada, China, Japan, 
Nigeria, the United Kingdom and the United States to develop a public resource to help 
researchers find genes affecting health, disease, and responses to drugs and environmental 
factors [9]. The international Hap-Map Project describes the common patterns of human DNA 
sequence variation and was built with the goal to develop a haplotype map of the human 
genome. The information produced by the Project is freely available. 
1.2 HARDY-WEINBERG EQUILIBRIUM 
The Hardy-Weinberg Equilibrium (HWE) law is the cornerstone of diploid population genetics 
[10]. It states that both allele and genotype frequencies in a population are in equilibrium from 
generation to generation unless specific disturbing influences (including non-random mating, 
mutations, selection, limited population size, "overlapping generations", random genetic drift, 
gene flow and meiotic drive) break this balance. Prior to performing association analyses 
between genetic maters and traits, genotype frequencies are tested for HWE [10].  
As a quick review, sites in the genome where the DNA sequences of many individuals 
differ by a single base are called single nucleotide polymorphisms (SNPs). For example, some 
people may have a chromosome with a C at a particular site where others have a chromosome 
with a T; each different letter (nitrogenous base) is called an allele. 
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1.3 SIRTUINS 
Sirtuins are proteins that have been reported to influence aging, stress and metabolism [11]. 
These proteins are localized in the mitochondria; the reason of the sub cellular localization is 
because these proteins in the human genome shared both a non-variable Sirt2 catalytic core 
domain and a variable amino- and carboxyl-terminal extensions [11]. 
Since mitochondrial contain some sirtuins and are the principal organ in charge of the 
energy output[11], scientific research has been involved in the process of illnesses such as 
diabetes, aging, neurodegenerative disorders and cancer with mitochondrial dysfunctions [12-
14]. The suggestion to address a relation between sirtuins and mitochondrial dysfunction is due 
to the acetylating process factor. It has been observed that during the well nutrition state the 
mitochondrial proteins are mostly acetylated [15, 16], but in the diet with considerable depletion 
of calories the acetylated-protein levels vary [15, 17]; thus, it is suggested that multiple enzymes 
depend on the removal of the acetyl groups from sirtuins to work properly. Also it is inferred that 
because of their role to preserve the proper function of the mitochondria, sirtuins are related in 
different disease processes (i.e. chronic and degenerative diseases). 
Their catalytic activity may be controlled by their chemical structure [11]. New research 
has revealed that sirtuins regulate the metabolism through the modulation of metabolic enzymes 
via protein deacetylation or mono-ADP-ribosylation, acting as clout in the metabolic efficiency 
[11]. The specific enzymes that catalyze the removal of acetyl groups from the (epsilon)-amino 
group of lysine residues are the Histone/Protein deacetylases [11]. Histone deacetylases are 
classified in three classes (I-III), and sirtuins belong to class III because of a distinctive chemical 
reaction which consumes nicotinamide adenine dinucleotide (NAD+) and generates 
nicotinamide, O-acetyl-ADP-ribose (OAADRr), and deacetylated substrate [18-20]. Sirtuins do 
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not belong to class I and II because proteins in those classes only catalyze simple hydrolysis of 
acetyllysine [21, 22].  
Currently, there are seven sirtuins known to be present in the human genome [23, 24]. 
SIRT1, SIRT2, SIRT6, SIRT7, SIRT3, SIRT4 and SIRT5 have different sub cellular locations 
and targets: SIRT1 is the nucleus and acts as a transcriptional repressor via histone deacetylation, 
regulating the transcription factors such as, MyoD, FOXO, p53, and NF-(KAPPA)B [25-31]. 
SIRT2 is in the cytoplasm and is related with the microtubules and deacetylates lysine of (alpha) 
tubulin [32]. SIRT6 is also in the cytoplasm and acts as histone H3K9 deacetylase to regulate 
telomeric chromatine [33]. SIRT7 is found in the nucleolus and regulates the RNA polymerase I 
transcription [34]. SIRT3, SIRT4 and SIRT5—all from the mitochondrial matrix—have 
controversial functions; SIRT 3 and 5 are NAD+ dependent deacetylases, which means they 
change the acetyl lysine proteins by taking off their acetyl groups to compose the 2’-O-acetyl-
ADP-ribose and nicotinamide. One of the functions of SIRT4 is to remove the ADP-ribose group 
[11]. 
1.4 SIRTUIN 5 
SIRT5 is an endogenous protein localized in the matrix of the mitochondria [11, 29]. It is located 
specifically in the mitochondria intermembrane space [35, 36]. Molecularly, it has 36 amino acid 
mitochondrial targeting signals in its N terminal which is removed once in the mitochondria [37, 
38]. SIRT5 is expressed in multiple tissues: brain, muscle, heart, liver and kidney [37, 39]. 
Recent findings show that a polymorphism in SIRT5 (rs9382222) is associated with 
molecular aging. This polymorphism has been located it in a mouse/human conserved region 
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using two separate programs to contain a promoter [40], such as TSSG CGG Nucleotide 
Sequence Analysis and Promoter 2.0. 
SIRT5 has a deacetylase function. SIRT5 acts on acetylated histones or BSA28 against 
acetylated histone H4 peptide, showing its deacetylase activity, and against acetylated 
cytochrome C30, intermembrane mitochondrial space protein [41]. 
Biologically, carbamoil phosphate synthase (CPS1) –a mitochondrial matrix enzyme– has 
been identified as a substrate for SIRT5. CPS1 plays an important role in urea synthesis in the 
urea cycle. In fact, this enzyme acts as a rate-limiting enzyme modulating the urea synthesis. 
Specifically, CPS1 removes the ammonia generated by amino acid catabolism [42, 43]. SIRT5 
increases the CPS1 activity because SIRT5 stimulates the deacetylation function of CPS1 with 
NAD+ in vitro[38]. Thus, SIRT5 increase the urea formation in conditions when the nutrient 
intakes are low, the ammonia generation is high, and the amino acid catabolism is also high [11]. 
A loss of ammonia is seen in metabolism with low calorie intake and high-protein diet (HPD), 
and this is when SIRT 5 regulates CPS1 [11]. 
A reduced calorie condition is a circumstance that regulates the SIRT5 expression. Once 
the calorie restriction begins the SIRT 5 start to deacetylate CPS1 triggering the activity of CPS1 
enzyme; this activation causes the exchange of ammonia in carbamoyl phosphate. This exchange 
consequently causes the excretion of carbamoyl phosphate as urea in the urea cycle [11]. 
New findings have shown a controversy about whether or not SIRT5 increase acetylation 
and/or hyperacetylation of CPS1 during diets with calorie restrictions [17]. Researchers based 
this theory on an experiment where, under a low calorie intake diet, they study the acetylation of 
the CPS1; the results show that 24 sites were acetylated but seven sites were hyperacetylated. In 
that study no site was found as deacetylated [17].  
 7 
Other studies has shown nine acetylating sites in CPS1, but in contrast with other 
experiments it shows that 4 sites were acetylated during feeding and fasting, another 4 sites were 
acetylated upon fasting, and one site was deacetylated [15]. 
SIRT5 activity remains under study due to these controversial results from different 
biased experiments. These studies generally suggest that SIRT5 could be related to other 
mitochondrial substrates [38], although new studies and concordant results are needed to 
understand in depth the activity of SIRT5 and clarify its blurred functions. The SIRT5 gene has 
also been correlated with malignancies [39]. 
1.4.1 SIRT5 and age-of-onset for neurological diseases 
The biological mechanism or pathways by which characteristics of age-of-onset for neurological 
diseases are expressed are mostly unknown, but the connection between transcriptome changes 
(“molecular aging”) and normal brain aging has been reported [40]. 
A cross-cohort microarray analysis found that many neurological disease pathways are 
associated with molecular aging [40]. From five candidates of longevity gene polymorphism, the 
SIRT5 gene (longevity gene) was used in this study. In fact, this research associated the low-
expressing polymorphism of this specific gene with older brain molecular ages [40]. Moreover, 
SIRT5 was suggested as a risk factor since it influences positively the proper function of the 
mitochondria. 
Many genes working as transcription regulators have been identified. Previous research 
about the relation between genes and neurological diseases has suggested that their expression 
promotes positively the progression of the disease. Some studies have been focused on finding a 
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relation between the sirtuin mechanism and different pathways to address preventive methods 
and treatments for neurological diseases. 
Based on previous post-mortem studies, subjects carrying the SIRT5 risk allele may be at 
increased risk for mitochondrial function- and age-related early declines [40]. These studies 
suggest that SIRT5 is associated with a downward spiral of aging and low expression of 
structural and functional markers of brain health. Thus, the purpose of the current study is to 
investigate the associations between the risk allele SIRT5 and three functional markers of brain 
health in the Health ABC epidemiological cohort. These associations may clarify the role of the 
risk allele SIRT 5 and the low expressions of functional markers of brain health and assist in 
early protection from the detrimental age-dependent effects. 
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2.0  HYPOTHESIS 
At baseline, subjects carrying the common C/C "risk" genotype at the SIRT5 SNP (rs9382222), 
which has been associated with older biological age of the brain, will display poorer function on 
cognitive function tests (lower DSST score) and motor function tests (longer time to walk 20 
meters), and have increased self-reported symptoms of a depressed mood (higher CES-D score), 
as compared to all other subjects. 
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3.0  METHODS 
3.1 POPULATION 
The Health, Aging and Body Composition (Health ABC) database [44] was chosen due to its 
large scale prospective investigation of multiple factors in subjects 65 years of age and older, 
consistent domain monitoring across studies and extensive expertise in the analysis of those data. 
The Health ABC is a longitudinal cohort study which from 1997 to 1998 enrolled 3,075 
Medicare affiliated eligible healthy individuals aged 70-79 years from Pittsburgh, Pennsylvania 
and Memphis, Tennessee. The cohort consisted of 52% women and 42% blacks with a mean age 
of 73.6 years. The Process of recruitment consisted of contacting Medicare affiliated eligible 
people; the information was obtained through the Centers for Medicare & Medicaid Services 
(once called the Health Care Financing Administration). Samples of the white and black 
populations were taken randomly through predesigned zip code areas near the Health ABC 
designed centers. Also eligible people from household members were also included in the 
population samples [45]. Since well-functioning individuals were included in this study the 
exclusion criteria were difficulty to perform basic daily activities such as difficulty walking. 
People who reported trouble walking at least one quarter of a mile and climbing ten steps without 
resting were also excluded [45]. Depressive symptoms were not recorded as part of the exclusion 
criteria. Less than 3% of the eligible people reported the use of anti-depressive medications [46]. 
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Based in the use of three continuous outcome measurements (functional markers of brain 
health) and a categorical exposure variable (the genotype: C/C, C/T, T/T). The estimation of the 
sample size was based in the assumption that we will do 3 T-test (using the formula for a T-test 
and Bonferroni-corrected alpha – i.e., 0.5 / 3 = 0.17). Our sample calculation in the design 
indicated us that with our sample size of 2768 we have enough power (80%) to detect as specific 
standard deviation as the 0.08 (Figure 1). 
 
 
Figure 1. Estimated sample sizes assuming a power of 80%, and alpha = 0.17 (0.5 / 3). It is observed 
that with the sample size of 1806 individuals we can detect a specific standard deviation as the 0.08. 
3.2 CLINICAL/DEMOGRAPHIC DATA 
The data from the Health ABC were used to find associations between a SIRT5 SNP and three 
functional markers of brain health. These three markers or variables of interest were based on in 
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the results of three standardized tests: the Cognitive test, Digit Symbol Substitution Test (DSST); 
Motor function test, Gait speed measure; and the Mood or depressive symptoms test, Center for 
Epidemiology Studies Depression Scale (CES-D). While these measures may not be as refined or 
sensitive as other approaches, there are highly appropriate for epidemiologic settings, and also 
these measures are useful in studying older populations [44, 47, 48]. 
3.3 BRAIN FUNCTION TESTS 
3.3.1 Cognitive test 
The Digit symbol substitution test (DSST) is a pencil and paper test of psychomotor 
performance, which requires incidental memory, perceptual organization, visuomotor 
coordination, selective attention and the ability to filter out irrelevant information (e.g., symbols 
that may look alike)[49]. This test is associated with mood [50], mobility [51] and physical 
disability [10]. In this test people are provided with a key grid of numbers and matching symbols 
together with a test section with numbers and empty boxes. The process of this test consists of 
filling out as many empty boxes as possible with a symbol matching each number in 90 seconds; 
in other words, it consists of encoding and retrieving numbers and matching symbols. Basically, 
in order to solve the DSST, people must memorize the encoded number in the test section which 
is temporarily stored, and then visually scan the key grid to search for the number-symbol match. 
Once the number is recognized they must match the symbols in the test section and copy those 
below each matched number. The score is given by correct number-symbol matches. The 
reliability of this test is high [52]. 
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3.3.2 Motor function test 
Gait Test is a reliable and valid measure of motor performance. This test measures the time 
people take to walk 20 meters from a stand-still position to a straight course setup along a 
hallway [53]. Using a stopwatch, the time was recorded from the first step people take until the 
last step at the end of the 20 meters. The detailed process consisted in asking participants to stand 
at a starting line marked with tape and, after the staff’s indication, start to walk normally until the 
finish line. 
3.3.3 Mood or depressive symptoms test 
The Center for Epidemiologic Studies Depression scale (CES-D) is a short self-report scale 
designed to measure depressive symptomatology in the general population. It has been widely 
used in studies of late-life depression [51]. CES-D was initially developed to measure depression 
symptoms in community samples [54]. Today it is considered a sensitive measure for general 
emotional distress [55, 56]. This scale has good psychometric properties [51]. The CES-D has 
demonstrated good test-retest reliability, validity in older adults [54] across different ethnic/racial 
populations [57], as well as high correlations with significant life events and clinical diagnosis of 
depression [54, 58, 59]. The scores obtained from the questionnaire responses range from 0 to 
60, with higher scores indicating more symptoms of depression [54]. CES-D scores of 16 to 26 
are considered indicative of mild depression and scores of 27 or more indicative of major 
depression [60]. We chose to use the CES-D since elevated scores are associated with current 
and future cognitive and motor impairment in the Health ABC [44, 47, 48], thus allowing our 
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hypothesis tests of low mood as a putative indicator for overall age-related decline in subjects at 
elevated biological risk. 
3.4 HAP-MAP PROJECT 
The International Hap-Map Project was used to compare the allele frequency of SIRT5 SNP 
versus the genotypes obtained in the Health ABC. White and black populations from the Health 
ABC database genotype frequencies were compared to the Hap-Map project. In the Hap-Map 
project the Yoruba in Ibadan Nigeria (YRI) were used as the black population and Utah residents 
with ancestry from northern and western Europe (CEU) as the white population. In addition, 
through the SIRT5 SNP information from the Hap-map project, we identified the respective 
genotype (C/C, C/T, T/T) for the Health ABC database genotype coded in numbers (0,1,2). 
3.5 HARDY-WEINBERG EQUILIBRIUM 
We listed the counts of the genotype distributions because the database with the rs9382222 SNP 
genotypes was already tested for HWE. This test can indicate if there are data-acquisition flaws 
or violations of assumptions of no mutation, selection, population substructure, etc. 
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3.6 ANCESTRY GENETIC POPULATION ASSUMPTION 
Because of the assumption that members of a preconceived “race” share common ancestry that 
may include genetic risk factors [61] and also because the Health ABC was divided into white 
and black populations, we separated the database by both races; in other words, all analyses were 
performed on each of the function measures separately by race, (European American–white 
population and African American–black population). Once the databases were stratified by race, 
contingency tables and chi-square tests were used to assess associations between frequencies of 
SIRT5 SNP (rs9382222) and distributions by race. 
3.7 BRAIN FUNCTION MARKERS: NORMAL 
DISTRIBUTION/TRANSFORMATION 
The distributions of the three brain function markers were examined: Cognition test, Motor 
function test and Mood or depressive symptoms test. We also transformed the distributions as 
necessary until the three brain function markers were normally distributed. 
3.8 STATISTICAL ANALYSIS 
3.8.1 Exploratory analysis 
The following variables from the Health ABC database were used: for phenotype, age 
(CVAGE), sex (GENDER), race (RACE), cognition test (Y1DSS), motor function test 
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(Y1MTR20SD) and mood or depressive symptoms test (Y1CES_D); for genotype, SIRT5 SNP 
(rs9382222). 
We tested for significant association and correlation between the three functional outcomes 
(CES-D, DSST and Gait speed test) and two independent variables (sex and age) using chi-
square and Pearson correlation statistics. These analyses were guided by previous analyses of 
these traits in the Health ABC cohort, e.g., Rosano et al., 2005. 
3.8.2 Main Analysis 
One way analysis of covariance (ANCOVA) was performed using SAS GLM procedure to test 
for between-group differences in functional outcomes (CES-D score, DSST score and Gait Test 
score) and two covariates (sex and age). The statistically significant models were selected and 
subsequently, we tested for association the three possible genotypes of SIRT 5 SNP (C/C, C/T, 
T/T). Finally, all the selected models with statistically significant differences among the three 
possible SIRT5 genotypes were plotted using box plots to show the differences among the three 
brain functional markers (test scores) in people carrying any of the three possible genotypes of 
SIRT5 SNP. 
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4.0  RESULTS 
4.1 HEALTH ABC DATABASE AND HAP-MAP PROJECT GENOTYPE 
COMPARISON 
The genotype frequencies in the Health ABC database compared to the Hap-Map project 
respectively, were as follows: in the white population, the common homozygote (CC) was 
47.02% vs. 43.3%, heterozygote (CT) was 42.57% vs. 46.7% and uncommon homozygote (TT) 
was 10.41% vs. 10%; in black population the common homozygote (CC) was 67.85% vs. 78.9%, 
heterozygote (CT) was 28.15% vs. 19.3% and uncommon homozygote (TT) was 4% vs. 1.8% 
(Figure 2). In addition, from the SNP information of the Hap-Map project, we identified the 
respective allele pair of bases (letters) to the registered Health ABC allele codes (numbers): 
C/C= 0, C/T=1, T/T=2. 
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Figure 2. Genotype frequencies of the HAP-MAP project (above) and the Health ABC database. 
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4.2 HARDY-WEINBERG EQUILIBRIUM 
The counts of the genotype distributions are listed in Table 1. 
Table 1. Genotype and Allele Frequencies in the Health ABC database. 
 Genotype Frequencies  Allele Frequencies  
Population Genotype Frequency Count Allele Frequency Count 
Health C/C 55.49 1536 C 73.84 2044 
ABC C/T 36.71 1016 T 26.51 724 
Database T/T 7.08 216    
Total  100 2768  100 2768 
4.3 SNP DISTRIBUTION BY RACE 
After the Health ABC data base was stratified by race, the following results were obtained in the 
association in the SNP distribution by race (χ2 125.3323, P <.0001): from the 2768 total 
population, 1642 (59.32%) were white and 1126 (40.68%) were black. Regarding the genotype 
distribution by race, among the white people, 772 (47.02%) were homozygote for the common 
allele, 699 (42.57%) were heterozygote and 171 (10.41%) were homozygotes with uncommon 
allele; among the black people, 764 (67.85%) were homozygotes for the common allele, 317 
(28.15%) were heterozygotes and 45 (4%) were uncommon allele homozygotes (Table 2) 
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Table 2. Distribution of the SIRT 5 SNP in white and black population. 
SNP/ 
RACE 
C/C C/T T/T TOTAL 
WHITE 47.02% 42.57% 10.41% 100% 
BLACK 67.85% 28.15% 4% 100% 
4.4 BRAIN FUNCTION MARKERS: NORMAL DISTRIBUTION / 
TRANSFORMATION 
DSST (Skewness: -0.2416207, Kurtosis: -0.0529059) and Gait (Skewness: 0.2172326, Kurtosis: 
0.31890667) showed a normal distribution. CES-D (Skewness: 2.06812055, Kurtosis: 
6.14335799) did not show a normal distribution and was transformed by logarithms (base 10) to 
reduce non-normality (Skewness: -0.0467108, Kurtosis: -0.7317499) (Figure 3). As additional 
information the Skewness and Kurtosis for a normal distribution is zero, and any symmetric data 
should have these values near zero. 
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Figure 3. Normal distribution graphs of the three brain functional markers. DSST (mean=35.39, 
SD=14.55), Gait Test (mean=1.33, SD=0.25) and CES-D Log 10 transformed (mean=0.61, SD=0.37) resulted with a 
normal distribution transformation. CES-D (without transformation) was not normally distributed. 
4.5 STATISTICAL ANALYSIS 
 
4.5.1 Analyses of Covariate effects on DSST, Gait Test and CES-D. 
The exploratory analysis resulted in the following significant associations: the associations 
between DSST score and sex in the white population showed a higher mean in females (43.0530 
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vs. 39.0279; t= -6.88, p <.0001) than males (Figure 4). The association between DSST score and 
sex in the black population showed a higher mean in females (29.6582 vs. 23.7655; t= -6.97, p 
<.0001) than males (Figure 4). The association between Gait Test and sex in the white 
population showed a higher mean in males (1.4607 vs. 1.3385; t= 10.15, p <.0001) than females 
(Figure 5). The association between Gait Test and sex in the black population showed a higher 
mean in males (1.2964 vs. 1.1707; t= 8.63, p <.0001) than females (Figure 5). The association 
between CES-D score and sex in the white population showed a higher mean in females (5.3912 
vs. 3.9606; t= -4.60, p <.0001 ) than males (Figure 6Figure 7). The association between CES-D 
score and sex in the black population resulted in no significant association although there was a 
higher mean in females (5.021 vs. 4.560; t= -0.37, p <0.7094) than males (Figure 6 Figure 7). In 
addition, the exploratory analysis results in the following significant correlations: DSST score 
and age in white population showed a significant negative correlation - white subjects with older 
ages tend to have lower DSST scores (Pearson correlation: -0.17968, p <0.0001) (Figure 8). 
DSST scores and age in black population showed a significant negative correlation: black 
subjects with older ages tend to have lower DSST scores (Pearson correlation: -0.20233, p 
<0.0001) (Figure 8). Gait test and age in white population showed a significant negative 
correlation: subjects with older ages tend to have lower Gait Test scores (Pearson correlation -
0.1562, p <0.0001) (Figure 9). Gait Test and age in black population showed a significant 
negative correlation: subjects with older ages tend to have lower Gait Test scores (Pearson 
correlation: -0.19153, p <0.0001) (Figure 9). CES-D and age resulted in no significant 
correlation in either white (Pearson correlation:-0.00267, p =0.9233) or black (Pearson 
correlation: 0.02962, p =0.3791) populations (Figure 10 &Figure 11). These results are 
summarized in Table 3. 
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Figure 4. Graphs of DSST score by sex and stratified by race. 
 
Figure 5. Figure Graphs of Gait Test score by sex and stratified by race. 
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Figure 6. Graphs of CES-D (without transformation) score by sex and stratified by race. 
 
Figure 7. Graphs of CES-D (Log 10 scale transformed) by sex and stratified by race. 
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Figure 8. Graphs of DSST score by age and stratified by race. 
 
Figure 9. Graphs of Gait Test score by age and stratified by race. 
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Figure 10. Graphs of CES-D (without transformation) score by age and stratified by race. 
 
Figure 11. Graphs of CES-D (Log 10 scale transformed) by age and stratified by race. 
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Table 3. Summary of results from the analyses of Covariate effects on DSST, Gait Test and CES-D. 
 Variable DSST Gait Test CES-D 
White 
Population 
AGE YES 
Correlation  
(Pearson= -
0.17968,  
p <0.0001) 
YES 
Correlation 
 (Pearson= -
0.1562, 
 p <0.0001) 
NO Correlation 
(Pearson= -
0.00267, p 
0.9233)  
 SEX YES 
Association 
(t= -6.88, p 
<0.0001) 
YES 
Association 
(t= 10.15, p 
<0.0001) 
YES Association 
(t= -4.60, p 
<0.0001) 
Black 
Population 
AGE YES 
Correlation 
(Pearson: -
0.20233,  
p <0.0001) 
YES 
Correlation  
(Pearson: -
0.19153,  
p <0.0001) 
NO Correlation  
(Pearson:0.02962,  
p 0.3791 ) 
 SEX YES 
Association 
(t= -6.97, p 
<0.0001) 
YES 
Association 
(t= 8.63, p 
<0.0001) 
NO Association  
(t= -0.37, p 
<0.7094) 
 
4.5.2 Association with SIRT5 SNP 
Based on the associations and correlations among the three functional outcomes of brain health 
(DSST, Gait Test and CES-D) and the independent variables (age and sex), the following models 
were run (Table 4) and graphed (Figure 12). The results of each of the designed models are 
summarized in Table 5; the first five models were statistically significant: Model 1 (F= 33.36, p 
<0.001), Model 2 (F= 32.89, p <0.001), Model 3 (F= 50.32, p<0.001), Model 4 (F= 41.25, p 
<0.001), Model 5 (F= 12.61, p <0.001). Model 6 was not statistically significant (F= 0.64, p 
<0.526). 
From the overall models (Table 5) only models 2 and 5 were significant for the SIRT5 
SNP: in Model 2, people lost 0.94 units for every year of age and the emphasis on sex in the 
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model made people increase 5.65 units, both changes in the DSST; in Model 5, the SIRT 5 SNP 
effect of sex in the model made people lose 0.09 units in the CES-D. The results from the rest of 
the Models (not statistically significant) were as follows: in model 1, people lost 0.72 units for 
every year of age and the emphasis on sex in the model made people increase 3.83 units in the 
DSST; in Model 3, people lost 0.01 units for every year of age and the emphasis of sex in the 
model made people lose 0.12 units in Gait test; and in Model 4, people lost by 0.01 units for 
every year of age and the emphasis of sex in this Model made people lose 0.13 units. 
 
Table 4. Models designed for the association with SIRT5 SNP. 
No. Outcome Model F-test Significant 
 DSST    
1 WHITE DSST= β0 + β1 x GENOTYPE + β2 x 
AGE + β3 x SEX 
33.36, p <0.001 Yes 
2 BLACK DSST= β0 + β1 x GENOTYPE + β2 x 
AGE + β3 x SEX 
32.89, p <0.001 Yes 
 Gait Test    
3 WHITE Gait T= β0 + β1 x GENOTYPE + β2 
x AGE + β3 x SEX 
50.32, p <0.001 Yes 
4 BLACK Gait T= β0 + β1 x GENOTYPE + β2 
x AGE + β3 x SEX 
41.25, p <0.001 Yes 
 CES-D    
5 WHITE CES_D= β0 + β1 x GENOTYPE + β2 
x SEX 
12.61, p <0.001 Yes 
6 BLACK 
(ANOVA) 
CES_D= β0 + β1 x GENOTYPE  0.64, p <0.526 No 
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Figure 12. Graphs of each Model designed for the association with SIRT5 SNP. Model 1: DSST in white 
population= β0 + β1 GENOTYPE + β2 x AGE + β3 x SEX (F 33.36, p<0.001); Model 2: DSST in black population= 
β0 + β1 x GENOTYPE + β2 x AGE + β3 x SEX (F 32.89, p<0.001 ); Model 3: Gait Test in white population = β0 + β1 
x GENOTYPE + β2 x AGE + β3 x SEX (F 50.32, p<0.001); Model 4: Gait Test in black population= β0 + β1 x 
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GENOTYPE + β2 x AGE + β3 x SEX (F 41.25, p<0.001); Model 5: CES-D in white population = β0 + β1 x 
GENOTYPE + β2 x SEX (F 50.32, p<0.001) (Log 10 scale transformed); Model 6: CES-D in black population = β0 
+ β1 x GENOTYPE (F 1.03, p<0.358) (Log 10 scale transformed); Model 5: CES-D in white population = β0 + β1 x 
GENOTYPE + β2 x SEX (without transformation); Model 6: CES-D in black population = β0 + β1 x GENOTYPE 
(without transformation). 
*Last two graphs about model 5 and 6 using untransformed data were showed as a reference to appreciate the 
changes in the relation compared to the non-log 10 transformed CES-D scores. 
 
Table 5. Summary of results from the association with SIRT5 SNP. 
Model 
Number 
Outcome/Race Model’s 
Variables 
Parameter 
Estimate 
t Value  Pr > |t| 
1 DSST/White Intercept 88.6300 11.69 <.0001 
  RS938222 0.2495 0.58 0.5651 
  AGE -0.7255 -7.15 <.0001 
  SEX 3.8386 6.65 <.0001 
2 DSST/Black Intercept 87.35 8.24 <.0001 
  RS938222 1.45 1.97 0.0486 
  AGE -0.9487 -6.66 <.0001 
  SEX 5.6574 6.82 <.0001 
3 Gait Test/White Intercept 2.6148 16.77 <.0001 
  RS938222 -0.0011 -0.12 0.9017 
  AGE -0.0139 -6.67 <.0001 
  SEX -0.1250 -10.55 <.0001 
4 Gait Test/Black Intercept 2.6118 14.28 <.0001 
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  RS938222 0.0065 0.52 0.6024 
  AGE -0.0161 -6.56 <.0001 
  SEX -0.1307 -9.16 <.0001 
5 CES-D/White Intercept 0.45136 1.62 0.1052 
  RS938222 -0.03185 -2.04 0.0419 
  AGE 0.00035 0.10 0.9239 
  SEX 0.09711 4.63 <.0001 
6 CES-D/Black Intercept 0.3333 1.02 0.3064 
  RS938222 -0.0165 -0.72 0.4702 
  AGE 0.0039 0.90 0.3668 
  SEX 0.0099 0.39 0.6977 
 
From the Models 2 and 5 (Table 6) which were selected to be tested for their association 
among each of the three possible genotypes of SIRT5 SNP (C/C, C/T & TT), only Model 2 had 
found a borderline significant association in the genotype C/C vs. C/T (common homozygote vs. 
heterozygote) with a statistically significant difference of p=0.051, mean difference=-0.05, 
Standard Deviation=0.95, (Table 7)(Figure 13); in other words, in the black population, the 
recessive allele “T” causes the DSST score to increase, or vice-versa. The dominant allele “C” 
makes the DSST score decrease. Model 5 had an association between the genotype C/C vs. C/T 
(common homozygotes vs. heterozygotes); however, the statistical significance was p=0.08, 
mean difference=-1.85, Standard deviation=0.03 (Table 8). 
 
Table 5 continued 
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4.5.2.1 DSST 
In this test, which were involved models 1 and 2, just model 2 had found a borderline 
significant association in the genotype C/C vs. C/T (common homozygote vs. heterozygote) with 
a statistically significant difference of p=0.051, mean difference=-0.05, Standard Deviation=0.95 
(Table 7)(Figure 13). 
4.5.2.2 Gait Test 
Models 3 and 4 were involved in this specific test and neither of these models was 
statistically significant associated to the genotype. 
4.5.2.3 CES-D 
In this test, which were involved in models 5 and 6, just model 5 had an association 
between the genotype C/C vs. C/T (common homozygotes vs. heterozygotes); however, the 
statistical significance was p=0.08, mean difference=-1.85, Standard deviation=0.03 (Table 8). 
 
Table 6. Models 2 and 5 divided by their three different genotype components (C/C, C/T, T/T). 
Model No. OUTCOME MODEL 
 DSST  
2 BLACK 
Population 
DSST= β0 + β1 x GENOTYPE0 + β2 x AGE + β3 x SEX 
DSST= β0 + β1 x GENOTYPE1 + β2 x AGE + β3 x SEX 
DSST= β0 + β1 x GENOTYPE2 + β2 x AGE + β3 x SEX 
 CES-D  
5 WHITE 
Population 
CES_D= β0 + β1 x GENOTYPE0 + β2 x SEX 
CES_D= β0 + β1 x GENOTYPE1 + β2 x SEX 
CES_D= β0 + β1 x GENOTYPE2 + β2 x SEX 
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Table 7. Comparison (T-test) among common homozygote C/C vs. heterozygote C/T from Model 2. 
DSST in black population= β0 + β1 x GENOTYPE (C/C,C/T) + β2 x AGE + β3 x SEX. 
Contrast SD t-value P-value 
Common 
Homozygote vs. 
Heterozygote 
0.956 1.950 0.051 
 
Table 8. Comparison (T-test) among common homozygote C/C vs. heterozygote C/T from Model 5. 
CES_D= β0 + β1 x GENOTYPE (C/C,C/T) + β2 x SEX.  
Contrast SD t-value P-value 
Common 
Homozygote vs. 
Heterozygote 
0.0352 1.73 0.0830 
 
 
                                      
Figure 13. Graph of Model 2 comparing two genotypes -C/C & C/T-. Model: DSST in back 
population= β0 + β1 x GENOTYPE (C/C, C/T) + β2 x AGE + β3 x SEX. 
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5.0  DISCUSSIONS 
In overall, the results confirmed our hypothesis because we expected that at baseline, subjects 
carrying the common C/C risk genotype, which has been associated with older biological age of 
brain, would display poorer brain functions (i.e. lower DSST score, higher reported depressive-
like symptoms) and we found that the C/C SIRT5 genotype was associated here with (1) lower 
DSST scores in the black population (almost 2 units lower than heterozygotes) and (2) displayed 
trend-level higher CES-D depressive-like scores in the white population, hence supporting the 
SIRT5 C/C genotype as a risk factor for both biological brain age and related functional 
outcomes. 
Since Health ABC is a sample of two populations in the United States (US) and Hap Map 
is a sample of international populations, the comparison was useful to describe the expected 
allele frequencies in the international population versus those reported in the Health ABC. 
If a particular genetic variant is in HWE then we can assume that there are unlikely to be 
data errors and that the assumptions of the association analyses are met, thus the analyses can 
proceed. If can also provide a baseline against with to measure change. 
The reason we stratified the Health ABC database in black and white population is 
because we expected variations in allele frequencies between the populations [61]. By analyzing 
the populations separately, we prevented confounding due to allele frequency differences. 
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As expected, the analysis of covariates showed that females tend to have higher DSST 
scores than males; while in Gait scores the tendency is the opposite. Also according to our 
expectations, this analysis shows that older populations have the propensity for lower scores in 
DSST and higher Gait scores. As for CES-D scores, the results showed that white females tend 
to report more depressive symptoms than males. In DSST heterozygotes, members of the black 
population are more likely to have almost 2 units more than common homozygotes. 
The Differences in CES-D among the white population are so small and the p-values are 
so far beyond the conventional 0.05 that it is not recommended to be considered. In fact, 
regarding our hypothesis, we expect people carrying the common genotype C/C report increasing 
depressive symptoms than people who do not carry these genotype; thus, although CES-D in 
white population was not statistically significant, the association between CES-D and the 
genotype was as expected. This finding is actually encouraging and should be followed up in 
other cohorts. 
The results from the association with SIRT5 SNP analyses indicated an association 
between DSST and SIRT 5 SNP in the black population. These results suggest that future studies 
need to confirm our hypothesis because we expected that at baseline, subjects carrying the 
uncommon genotype T/T would display poorer function on the cognitive function test (lower 
DSST score) and we observed that the common genotype C/C is a risk factor for lower DSST 
scores, however this difference was modest; thus, we can suppose that the uncommon genotype 
is a protective factor that prevents from people obtaining lower DSST scores, in relation those 
with the common genotype in the black population. 
Looking at these results from the allele perspective, we can say that the more SIRT5 “C” 
alleles people carry, the greater the risk for a lower DSST score. Alternatively, we could say that 
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people who carry the allele “T” have a protective factor to avoid lower DSST scores; for 
example, heterozygotes people C/T showed higher DSST scores than the most common 
homozygote individuals regarding their genotype SIRT5 SNP; thus, this assumption could mean 
that the allele “T” in heterozygotes is providing some kind of protection against the allele “C” in 
the DSST score. 
Height is an important factor in the gait test score; usually it is expected than taller people 
have lower gait test scores than shorter people; the reason for this anthropometric aspect is that 
taller people usually have longer lower limbs; thus, they need less time to walk 20 meters than 
people with shorter legs who need more steps to complete the test. This factor could affect our 
results and interpretation in terms of motor function. In order to avoid this possible distortion of 
to our findings, in future studies it is important to adjust this factor (group people with the same 
height in the motor test scores) in the main analysis. 
Because Health ABC selected healthy people, we can only make predictions between the 
SIRT 5 SNP and the three functional brain markers in the healthy older population, instead of an 
entire population (healthy and non-healthy individuals). In addition, we do not know if the 
association will show with prevalent, morbid cases.  However, the focus of health ABC is for 
example to focus on why healthy people become demented, not why sick people become 
demented. 
Cross-sectional studies usually involve observations of the entire population. However 
because Health ABC selected healthy people, we can only make predictions between the SIRT 5 
SNP and the three functional brain markers in the healthy older population, instead of an entire 
population. 
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Basically, because we are studying healthy people, there would be no advantage between 
the prospective cohort studies (help to determine risk factors with longitudinal observations over 
time) over the Cross-sectional studies (follow representative subset of the population, at a 
defined time) to find an association (SNP-functional markers of brain health). Although this can 
be easily tested by comparing the cross-sectional with prospective in future analyses 
Sample size is always an important factor in any research; the more individuals enrolled, 
the more accurate results will be obtained. Thus, the future use of different databases could affect 
the way these results are presented. 
Several factors may increase a woman's risk of depression that about twice as many 
women as men experience depression. Probably because this depression gender gap lasts until 
after menopause, women are still more sensitive to detect and report depressive symptoms than 
men. This gap could influence the CES-D scores among both sexes. 
Additional analyses could help our understanding of the association of SIRT5 alleles with 
brain function. For example, we could combine the three measures of brain function scores into 
one score, using principal components methods. This would enable a test of association between 
SIRT5 SNP and one multifunctional marker of brain health. Such a result could clarify the 
inherited interrelation of the three functional brain markers as a whole brain function associated 
with the SIRT5 SNP. 
5.1 LIMITATIONS 
However the Health ABC cohort is one of the most representative studies that have been done in 
the older population area, there still could be a collection bias. One major bias might be 
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individuals who are intellectually or physically disabled.  Also those having low vision or 
reading difficulties could be a problem. This systematic favoritism present in data collection 
could affect positively or negatively the results of the study. For example if they select people 
based in the zip codes near to the Health ABC centers, the educational level, amenities to 
facilitate sport activities from selected population could affect the scores of the three functional 
marker of brain health. In addition, there is no perfect way to test this. However, one could look 
at the characteristics of those who provide complete data over the years of the study and 
compared to those who do not.  Also, one could do test retest reliably. 
5.2 CONCLUSIONS 
The genotype frequency in the total population (Health ABC) tends to be the common 
homozygous C/C rather than heterozygous C/T and uncommon homozygous T/T. 
Mean DSST heterozygotes C/T among black population, are more likely to be 2 units 
higher than mean DSST for the common homozygotes C/C, indicating that heterozygotes have a 
better performance in the DSST score than those who carry the C/C genotype. 
Members of the black population who carry the common homozygote genotype C/C 
show a poorer performance in the DSST score than those who carry the heterozygote genotype 
C/T. 
We can also conclude that SIRT5 SNP is a risk or protective factor to the DSST score 
depending on its allele frequency expressed in the black population. Allele “C” is a risk factor 
for a poor DSST score and allele “T” is a protective factor for this same test. 
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Besides the functional markers of brain health we used, probably the finding for other 
tests could change the direction of our results. For example, DSST scores could be no as accurate 
as other cognitive tests for older population. More over the health status could be related with the 
success in the DSST. We could expect that disable individuals would obtain lower DSST scores 
than healthy individuals, but probably this expectation change using another cognitive test. Same 
could happen with the CES-D and Gait Test. 
The educational level also could be relevant to our results; it would be expected that 
people with higher education would obtain higher DSST scores than those who lack of this 
educational level; thus, if we do not aware the educational level of our selected population, we 
could overestimate our results by observing a stronger association between the SNP and the 
DSST. 
Differences in CES-D among the white population were not significant. Given the lack of 
statistically significant findings, differences in CES-D scores among the white population were 
not conclusive in this study; however, this finding is auspicious and should be followed up in 
other cohorts and studies. 
The lack of community health programs is a factor that also could influence the results of 
this study. The absence of recreational activities and psychological support from public health 
programs, at the time people were performing the CES-D and Gait Test, could underestimate the 
association of the SNP with both CES-D and Gait Test, since this activities enhance healthy 
cardiovascular condition and motivate people in their daily activities.  
Finally, regarding the null statistical significant association of Gait Test and the SNP, 
probably we could consider that this particular SNP is not relevant to this specific test and/or 
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there could be others SNPs which could show a stronger association with the motor function 
using the Gait Test or other kind of tests. 
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